Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Anavex Life Sciences Provides an Update on Rett Syndrome Program

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73)

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result